Spectranetics (Colorado Springs, Colorado) reported receiving FDA clearance for its peripheral atherectomy products, Turbo-Tandem and Turbo Elite, for the treatment of in-stent restenosis (ISR). The company said that the clearance prompts a new standard of care in ISR treatment with improved clinical outcomes.